Impact of Human Papillomavirus Vaccination in Reducing Cancer.

Human papillomavirus (HPV) is a significant cause of global morbidity and mortality. A nonavalent HPV vaccine is widely available and recommended for routine use at 11 to 12 years old. Older teens and adults though age 45 years also could be offered vaccination.